Negotiations on the retrieval of health insurance benefits paid for 60 choline alfoscerate products have all fell through despite the series of extensions made on its negotiation period. The key cause of the negotiation breakddown was that the payer, National Health Insurance Service (NHIS), and the pharmaceutical companies were unable to reach an agreement on the collection rate.

As a result, the government is now at a crossroads. It may either order deletion of the 60 products from the benefits list or order renegotiations.

According to industry officials on the 12th, NHIS reported to the Ministry of Health and Welfare that the negotiation between NHIS and relevant phar